3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
8
Unknown
2
Recruiting
2
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
6
Colorectal Neoplasms
4
Rectal Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Cisplatin
12
Cetuximab
9
pembrolizumab
7
Radiotherapy
7
Fluorouracil
6
Carboplatin
5
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
epacadostat
3
Radiation
3
Docetaxel
3
Venlafaxine Hydrochloride
2
Surveys and Questionnaires
2
Panitumumab
2
Paclitaxel
2
Ketamine
2
zimberelimab
1
vandetanib
1
tislelizumab
1
temsirolimus
1
ruxolitinib
1
plerixafor
1
nimotuzumab
1
linrodostat
1
fosbretabulin
1
fluoromisonidazole
1
fludarabine phosphate
1
fludarabine
1
elgemtumab
1
ebselen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Head and Neck Neoplasms
×
Neoadjuvant Therapy
×
Clear all
NCT03323424
2020-01-30
IRAM
Institut de Cancérologie de la Loire
Phase 2
Withdrawn